Abstract
Histone deacetylase inhibitors have generated keen interest as potential chemopreventive and chemotherapeutic agents due to their ability to induce cell cycle arrest, differentiation, and apoptosis in a diverse group of cancer derived cell lines. Activation of the 60 kDa non-receptor tyrosine kinase, c-Src, has been a consistent finding in many tumors and tumor derived cell lines, and has been implicated in these same cellular processes. We have shown that the histone deacetylase inhibitors, sodium butyrate and Trichostatin A, repressed c-Src mRNA and protein expression in a dose-dependent manner in cell lines derived from cancers of the colon, breast and liver. Our group has previously identified two distinct promoters that are responsible for SRC transcription, separated by a distance of approximately 1 kb. Sodium butyrate and Trichostatin A strongly inhibited activity of each of these highly disparate SRC promoters, demonstrating histone deacetylase inhibitors directly repress SRC transcription. This repression did not require protein neosynthesis and was not associated with a decrease in binding of protein factors essential for either promoter's activity. Our finding that sodium butyrate and Trichostatin A inhibit both SRC promoters suggest this oncogene may be a major target of these agents, and may explain in part their anti-cancer activity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Andrews NC, Faller DV . 1991 Nucleic Acids Res. 19: 2499
Archer SY, Meng S, Shei A, Hodin RA . 1998 Proc. Natl. Acad. Sci. USA 95: 6791–6796
Bannister AJ, Miska EA, Gorlich D, Kouzarides T . 2000 Curr. Biol. 10: 467–470
Biscardi JS, Belsches AP, Parsons SJ . 1998 Mol. Carcinog. 21: 261–272
Biscardi JS, Tice DA, Parsons SJ . 1999 Adv. Cancer Res. 76: 61–119
Bonham K, Fujita DJ . 1993 Oncogene 8: 1973–1981
Bonham K, Ritchie SA, Dehm SM, Snyder K, Boyd FM . 2000 J. Biol. Chem. 275: 37604–37611
Chiang CM, Roeder RG . 1995 Science 267: 531–536
Chomczynski P, Sacchi N . 1987 Anal. Biochem. 162: 156–159
Cuisset L, Tichonicky L, Jaffray P, Delpech M . 1997 J. Biol. Chem. 272: 24148–24153
D'Argenio G, Cosenza V, Della Cave M, Iovino P, Delle Valle N, Lombardi G, Mazzacca G . 1996 Gastroenterology 110: 1727–1734
Dehm S, Senger MA, Bonham K . 2001 FEBS Lett. 487: 367–371
Doetzlhofer A, Rotheneder H, Lagger G, Koranda M, Kurtev V, Brosch G, Wintersberger E, Seiser C . 1999 Mol. Cell. Biol. 19: 5504–5511
Espinos E, Le Van Thai A, Pomies C, Weber MJ . 1999 Mol. Cell. Biol. 19: 3474–3484
Foss FM, Veillette A, Sartor O, Rosen N, Bolen JB . 1989 Oncogene Res. 5: 13–23
Gamet L, Daviaud D, Denis-Pouxviel C, Remesy C, Murat JC . 1992 Int. J. Cancer 52: 286–289
Gu W, Roeder RG . 1997 Cell 90: 595–606
Hague A, Manning AM, Hanlon KA, Huschtscha LI, Hart D, Paraskeva C . 1993 Int. J. Cancer 55: 498–505
Han JW, Ahn SH, Kim YK, Bae GU, Yoon JW, Hong S, Lee HY, Lee YW, Lee HW . 2001 J. Biol. Chem. 276: 42084–42090
Hass R, Busche R, Luciano L, Reale E, Engelhardt WV . 1997 Gastroenterology 112: 875–881
Huang L, Sowa Y, Sakai T, Pardee AB . 2000 Oncogene 19: 5712–5719
Iacomino G, Tecce MF, Grimaldi C, Tosto M, Russo GL . 2001 Biochem. Biophys. Res. Commun. 285: 1280–1289
Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R, Yeatman TJ . 1999 Nat. Genet. 21: 187–190
Irby RB, Yeatman TJ . 2000 Oncogene 19: 5636–5642
Karni R, Jove R, Levitzki A . 1999 Oncogene 18: 4654–4662
Kouzarides T . 2000 EMBO J. 19: 1176–1179
Lee JS, Galvin KM, Shi Y . 1993 Proc. Natl. Acad. Sci. USA 90: 6145–6149
Luciano L, Hass R, Busche R, von Engelhardt R, Reale E . 1996 Cell Tissue Res. 286: 81–92
Mandal M, Kumar R . 1996 Cell. Growth Differ. 7: 311–318
Mariadason JM, Corner GA, Augenlicht LH . 2000 Cancer Res. 60: 4561–4572
Marks PA, Richon VM, Breslow R, Rifkind RA . 2001a Curr. Opin. Oncol. 13: 477–483
Marks PA, Rifkind RA, Richon VM, Breslow R . 2001b Clin. Cancer Res. 7: 759–760
Martinez-Balbas MA, Bauer UM, Nielsen SJ, Brehm A, Kouzarides T . 2000 EMBO J. 19: 662–671
Maruta H, Greer K, Rosenbaum JL . 1986 J. Cell Biol. 103: 571–579
McIntyre A, Gibson PR, Young GP . 1993 Gut 34: 386–391
Nakano K, Mizuno T, Sowa Y, Orita T, Yoshino T, Okuyama Y, Fujita T, Ohtani-Fujita N, Matsukawa Y, Tokino T, Yamagishi H, Oka T, Nomura H, Sakai T . 1997 J. Biol. Chem. 272: 22199–22206
Rajala RV, Dehm S, Bi X, Bonham K, Sharma RK . 2000 Biochem. Biophys. Res. Commun. 273: 1116–1120
Reddy BS . 1995 Crit. Rev. Food Sci. Nutr. 35: 175–190
Richon VM, Sandhoff TW, Rifkind RA, Marks PA . 2000 Proc. Natl. Acad. Sci. USA 97: 10014–10019
Ritchie S, Boyd FM, Wong J, Bonham K . 2000 J. Biol. Chem. 275: 847–854
Schwartz B, Avivi-Green C, Polak-Charcon S . 1998 Mol. Cell. Biochem. 188: 21–30
Sealy L, Chalkley R . 1978 Cell 14: 115–121
Singh B, Halestrap AP, Paraskeva C . 1997 Carcinogenesis 18: 1265–1270
Souleimani A, Asselin C . 1993 FEBS Lett. 326: 45–50
Soutoglou E, Papafotiou G, Katrakili N, Talianidis I . 2000 J. Biol. Chem. 275: 12515–12520
Sowa Y, Orita T, Minamikawa-Hiranabe S, Mizuno T, Nomura H, Sakai T . 1999 Cancer Res. 59: 4266–4270
Staley CA, Parikh NU, Gallick GE . 1997 Cell Growth Differ. 8: 269–274
Suzuki T, Yokozaki H, Kuniyasu H, Hayashi K, Naka K, Ono S, Ishikawa T, Tahara E, Yasui W . 2000 Int. J. Cancer 88: 992–997
Topping DL, Clifton PM . 2001 Physiol. Rev. 81: 1031–1064
Toscani A, Soprano DR, Soprano KJ . 1988 Oncogene Res. 3: 223–238
Trock B, Lanza E, Greenwald P . 1990 J. Natl. Cancer Inst. 82: 650–661
Van Lint C, Emiliani S, Verdin E . 1996 Gene Expression 5: 245–253
Verbeek BS, Vroom TM, Adriaansen-Slot SS, Ottenhoff-Kalff AE, Geertzema J, Hennipman A, Rijksen G . 1996 J. Pathol. 180: 383–388
Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I, Coombes RC . 2001 Clin. Cancer Res. 7: 971–976
Yoshida M, Kijima M, Akita M, Beppu T . 1990 J. Biol. Chem. 265: 17174–17179
Acknowledgements
This study was supported by operating grants to K Bonham from the Canadian Institute of Health Research (CIHR) and the Saskatchewan Cancer Agency. S Dehm was supported by a Natural Sciences and Engineering Research Council of Canada (NSERC) Scholarship.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kostyniuk, C., Dehm, S., Batten, D. et al. The ubiquitous and tissue specific promoters of the human SRC gene are repressed by inhibitors of histone deacetylases. Oncogene 21, 6340–6347 (2002). https://doi.org/10.1038/sj.onc.1205787
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205787
Keywords
This article is cited by
-
Upregulation of annexin A1 expression by butyrate in human melanoma cells induces invasion by inhibiting E-cadherin expression
Tumor Biology (2016)
-
SHP-1 sensitizes MCF-7 cells to trichostatin A-induced apoptosis by modulating PI3K-dependent events
Cell Death & Differentiation (2003)